Financial Solutions Advisory Group Inc. Makes New $610,000 Investment in Merck & Co., Inc. $MRK

Financial Solutions Advisory Group Inc. bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 5,069 shares of the company’s stock, valued at approximately $610,000.

A number of other institutional investors have also recently modified their holdings of MRK. Allen Capital Group LLC increased its stake in shares of Merck & Co., Inc. by 6.2% in the 1st quarter. Allen Capital Group LLC now owns 10,615 shares of the company’s stock valued at $1,277,000 after purchasing an additional 621 shares in the last quarter. Axiom Investment Management LLC acquired a new position in Merck & Co., Inc. in the 1st quarter worth about $868,000. Summitry LLC boosted its position in Merck & Co., Inc. by 16.4% during the first quarter. Summitry LLC now owns 5,890 shares of the company’s stock worth $709,000 after purchasing an additional 829 shares in the last quarter. WNY Asset Management LLC acquired a new stake in Merck & Co., Inc. in the first quarter valued at approximately $1,294,000. Finally, Raab & Moskowitz Asset Management LLC grew its holdings in Merck & Co., Inc. by 0.8% in the first quarter. Raab & Moskowitz Asset Management LLC now owns 52,718 shares of the company’s stock valued at $6,341,000 after purchasing an additional 437 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 0.5%

Shares of MRK opened at $130.49 on Friday. Merck & Co., Inc. has a 52-week low of $77.53 and a 52-week high of $135.05. The stock has a market cap of $322.28 billion, a PE ratio of 36.76, a price-to-earnings-growth ratio of 5.17 and a beta of 0.19. The firm’s fifty day moving average is $123.17 and its two-hundred day moving average is $118.46. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.22 earnings per share. Research analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRK. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. BMO Capital Markets upped their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.50.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.